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Abstract: 
 
BACKGROUND: Although increased myocardial salvage and reduced mortality are associated 
with timely thrombolytic therapy for acute myocardial infarction, some patients still experience 
delays in treatment. OBJECTIVES: To examine treatment times in patients with acute 
myocardial infarction treated with thrombolytic therapy and to determine whether delays in 
treatment are associated with mode of transportation to the hospital, age, sex, or race. 
METHODS: Medical records of 176 patients with acute myocardial infarction treated with 
thrombolytic therapy at a community hospital were reviewed and analyzed retrospectively. 
RESULTS: Median times for the interval between arrival at the hospital and acquisition of a 
diagnostic electrocardiogram (door-to-electrocardiography time) and the interval between arrival 
and start of thrombolytic therapy (door-to-drug time) were 6 minutes and 34 minutes, 
respectively. However, 76.1% of the patients met the recommendation of the American College 
of Cardiology/American Heart Association of door-to-electrocardiography time of 10 minutes, 
and 47.2% met the recommendation of door-to-drug time of 30 minutes or less. Door-to-drug 
times did not differ significantly according to race or mode of transportation to the hospital. 
Door-to-electrocardiography and electrocardiography-to-drug times were significantly longer for 
older patients than for younger patients (P = .005 and P < .001, respectively), and 
electrocardiography-to-drug times were significantly longer for females than for males (P = .01). 
CONCLUSIONS: With increased emphasis on recognition and rapid treatment of patients with 
acute myocardial infarction at highest risk for delays in treatment, that is, women and the elderly, 
benefits of thrombolytic therapy might be maximized. 
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Article: 
 
Patients with acute myocardial infarction should receive reperfusion therapy as soon as possible 
after the onset of signs and symptoms of the infarction. The Global Utilization of Streptokinase 
and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) study1 
recommended that for maximum benefits, thrombolytic therapy should be started within 90 
minutes of the onset of signs and symptoms. The Food and Drug Administration recommends 
that treatment with tissue plasminogen activator be started within 3 hours of the onset of signs 
and symptoms.2 The American College of Cardiology/American Heart Association (ACC)/AHA) 
guidelines3 recommend that thrombolytic therapy be started within 12 hours of the onset of signs 
and symptoms but emphasize that starting treatment within 6 hours is most beneficial. Shorter 
times between the onset of signs and symptoms and reperfusion are associated with benefits such 
as increased myocardial salvage and reduced mortality.4-7 However, some patients with acute 
myocardial infarction still experience delays in treatment with thrombolytic agents. 
 
In order to further study potential delays in treatment, treatment times are divided into intervals. 
A patient's response time, the symptom-to-door time, is the interval between the onset of signs 
and symptoms and arrival at the hospital. The door-to-drug time is the interval between arrival at 
the emergency department and the start of thrombolytic therapy. Because hospital personnel 
have no control over patients' symptom-to-door times, the goals of hospital staff have been to 
reduce the time between arrival and diagnostic electrocardiography (ECG), or door-to-ECG time, 
and the time between diagnostic ECG and the start of thrombolytic therapy, or ECG-to-drug 
time, in an effort to meet the ACC/AHA recommendations8 of obtaining an ECG indicative of 
myocardial infarction within 10 minutes after a patient's arrival and of starting reperfusion 
therapy within 30 minutes after the arrival. 
 
Newby et al9 examined symptom-to-door and door-to-drug times in AMI patients receiving 
thrombolytic therapy in the GUSTO-1 trial. Symptom-to-door times were longer in females and 
the elderly than in other patients. Door-to-drug times were longer in the elderly, females, and 
nonwhite minorities than in other patients. Not surprising, more adverse outcomes were 
associated with delays in start of treatment. Reasons for the delays included the finding that the 
elderly and females were more likely than other patients to have atypical initial signs and 
symptoms.9 Additionally, physicians' uncertainty about risks versus benefits when making the 
decision to treat elderly patients with thrombolytic therapy may have been greater.9 
 
A similar study10 done in Quebec found that although no delays occurred in obtaining ECGs for 
the elderly or for women, the delay between diagnostic ECG and the decision to administer 
thrombolytic treatment was significantly longer for women and the elderly. Median times from 
obtaining ECGs to making a decision were 17 minutes for women and 11 minutes for men; 
median door-to-drug times were 65 minutes and 57 minutes, respectively. Median door-to-drug 
times were 55 minutes for patients aged 65 years or less and 65 minutes for patients more than 
65 years old.10 Additional studies found similar delays in time between onset of signs and 
symptoms and start of treatment for women11-14 and the elderly.14,15 
 
Research is inconclusive as to whether symptom-to-door times and door-to-drug times are longer 
for African Americans than for whites. In a review of the literature, Lee16 concluded that blacks 
generally had longer symptom-to-door times than did whites. Newby et al9 found no significant 
differences between symptom-to-door times according to race; however, door-to-drug times 
were significantly longer for blacks and for other nonwhite minorities. Richards et al17 reported 
that symptom-to-door times tended to be longer for African Americans than for whites, although 
the difference was not statistically significant. Further research is needed to better understand if 
delays exist according to race and to determine the mechanisms of delays if delays exist. 
 
The North Carolina Coronary Acute Response ECG Study (NC CARES) was organized in 1994 
by Duke University Cooperative Cardiovascular Society to aid North Carolina hospitals in 
decreasing door-to-drug times. Sixteen medical centers located in eastern and central North 
Carolina participated in the study. The primary efforts were implementation of programs to 
reduce door-to-drug times, such as programs for patients with chest pain that involve obtaining 
ECGs before the patients arrive at the hospital or rapid recording of ECGs after the patients 
arrive. 
 
In one NC CARES study, Griffin et al11 found that start of thrombolytic therapy was delayed in 
the elderly, with a trend toward longer delays for women. These findings were preliminary, and 
replication with a larger sample size was needed to determine whether the start of thrombolytic 
therapy in AMI patients differs according to sex and age. The study reported here was designed 
to determine treatment times of AMI patients who received thrombolytic therapy at a community 
hospital and to determine if delays in treatment exist according to mode of transportation to the 
hospital, age, sex, or race. On the basis of the study by Griffin et al at the same community 
hospital, the following assumptions were made: 
 
* The door-to-ECG times would meet ACC/AHA and GUSTO recommendations because of the 
rapid ECG protocol used at this community hospital. 
* The door-to-ECG times would be longer for self-transported patients than for patients who 
arrived by ambulance. 
* Delays in treatment would be longer for older patients and female patients than for other 
patients. 
 
Methods 
 
Setting 
 
Alamance Regional Medical Center, a 238-bed regional medical center located in central North 
Carolina, was a participant in the NC CARES program. The primary focus of the emergency 
department staff at this community hospital is obtaining a standard 12-lead diagnostic ECG as 
rapidly as possible. Standing orders allow the nurses to obtain a standard 12-lead ECG as soon as 
patients are brought to the treatment area. Prehospital ECGs are not used at this facility. 
Prehospital communication by radio transmission alerts the emergency department staff of the 
pending arrival by ambulance of patients with suspected AMI. The rapid ECG protocol for this 
regional medical center is discussed in an earlier article.11 The cardiology staff at this community 
hospital do not perform primary percutaneous transluminal coronary angioplasty. 
 
Study Sample 
 
Participants in this study were selected during a 40-month period: November 1994 to February 
1998. All patients selected met all of the following study criteria: the patient's first ECG was 
diagnostic of AMI, the patient did not have prehospital ECG, and thrombolytic therapy was the 
initial form of treatment. A total of 224 patients with a diagnosis of AMI were treated with 
thrombolytic therapy during the study period. Of these, 41 were excluded from the study because 
their first ECG was not diagnostic, and 7 were excluded because of missing or incomplete data. 
Thus, the final study sample had a total of 176 patients. 
 
Data Collection 
 
Retrospective chart analysis was done as part of a continuous quality improvement project for 
the emergency department of the hospital. Therefore, informed consent from individual patients 
was not needed. Data collection was made possible through the implementation of the second 
phase of the National Registry of Myocardial Infarction (NRMI-2), which began in June 1994. 
NRMI is an ongoing observational phase 4 study supported by Genentech, Inc, South San 
Francisco, Calif. The NRMI examines practice patterns and outcomes in patients who have AMI. 
NRMI has been previously described.18 Dates and times of (1) the onset of signs and symptoms 
of AMI, (2) arrival at the hospital, (3) acquisition of first ECG, (4) acquisition of a diagnostic 
ECG, and (5) the start of drug therapy were obtained in accordance with the NRMI-2 guidelines. 
 
Symptom-to-door times were calculated by subtracting the time of onset of signs and symptoms 
of AMI reported by the patient from the time of arrival at the hospital. Door-to-ECG times were 
calculated by subtracting the time of arrival at the hospital from the time of acquisition of a 
diagnostic ECG. ECG-to-drug times were calculated by subtracting the time of acquisition of a 
diagnostic ECG from the time of initiation of thrombolytic therapy. Door-to-drug times were 
calculated by adding door-to-ECG and ECG-to-drug times. 
 
Statistical Analysis 
 
Mean and median symptom-to-door, door-to-ECG, ECG-to-drug, and overall door-to-drug times 
were calculated according to the method of transportation to the emergency department, age, sex, 
and race. Medians with 25th and 75th percentiles were calculated for continuous baseline 
variables. Categoric variables are expressed as percentages. The nonparametric Wilcoxon rank 
sum test was used to examine differences in continuous variables. All statistical results are 
unadjusted for other covariates. 
 
Results 
 
Characteristics of the Sample 
 
Baseline characteristics of the sample are given in Table 1. The sample was mostly male and 
mostly white, with a mean age of 61 years. 
 
Symptom-to-Door Time 
 
Figure 1 shows the distribution of symptom-to-door times for all 176 patients. The mean time 
was 228 minutes (3.8 hours); the median time was 97 minutes (1.6 hours). Times ranged from 15 
minutes to 5033 minutes (83.9 hours). Approximately three quarters (76.1%) of the patients had 
a symptom-to-door time of 3 hours or less. 
Table 1. Baseline characteristics 
 
 
 
Figure 1. Time between onset of sign and symptoms of acute myocardial infarction and arrival 
at the hospital (symptom-to-door time; total number of patients = 176). 
 
Door-to-ECG Time 
 
Figure 2 shows the distribution of the door-to-ECG times, by 5-minute intervals, for all 176 
patients. The mean door-to-ECG time was 7.53 minutes; the median time was 6 minutes. In 134 
patients (76.1 %), a diagnostic ECG was obtained within 10 minutes of arrival at the hospital. 
 
 
Figure 2. Time between arrival at the hospital and acquisition of a diagnostic electrocardiogram 
for patients with acute myocardial infarction (door-to-ECG time; total number of patients = 176). 
 
ECG-to-Drug Time 
 
Figure 3 shows the distribution of ECG-to-drug times, by 10-minute intervals, of all patients. 
The mean ECG-to-drug time was 33.2 minutes; the median time was 26 minutes. 
 
 
Figure 3. Time between acquisition of diagnostic electrocardiogram and start of thrombolytic 
therapy for patients with acute myocardial infarction (ECG-to-drug time; total number of patients 
= 176). 
 
 
 
 
Figure 4. Time between arrival at the hospital and start of thrombolytic therapy for patients with 
acute myocardial infarction (door-to-drug time; total number of patients = 176). 
 
Table 2. Time between arrival at the hospital and acquisition of a diagnostic electrocardiogram 
 
 
Door-to-Drug Time 
 
Figure 4 shows the distribution of the overall door-to-drug times for all patients. The times 
ranged from 10 minutes to 155 minutes (2.58 hours). The mean time was 40.74 minutes; the 
median time was 34 minutes. Nearly half of the patients (47.2%) received thrombolytic therapy 
within 30 minutes or less after arrival at the hospital. 
 
Comparison of Times According to Baseline Characteristics 
 
Symptom-to-door times did not differ significantly according to mode of transportation to the 
emergency department, age, sex, or race. 
 
The door to-ECG times according to baseline characteristics are given in Table 2. Door-to-ECG 
times did not differ significantly according to race or sex. However, differences between patients 
who arrived at the hospital by ambulance and patients who arrived via private vehicle were 
significant; median times were 5 minutes and 8 minutes, respectively. Also, patients less than 70 
years old had significantly shorter door-to-ECG times than did patients 70 years or older; median 
times were 5 minutes and 8 minutes, respectively. Outliers were included in all calculations. 
 
The ECG-to-drug times according to baseline characteristics are given in Table 3. ECG-to-drug 
times did not differ significantly according to mode of transportation to the hospital or race. 
However, ECG-to-drug times were significantly lower for patients less than 70 years old than for 
patients 70 years or older; median times were 24 minutes and 34 minutes, respectively. In 
addition, ECG-to-drug times differed significantly according to sex; females had longer times 
than did males. 
 
Table 3. Time between acquisition of a diagnostic electrocardiogram and start of thrombolytic 
theory 
 
 
Overall door-to-drug times according to baseline characteristics are given in Table 4. Overall 
door-to-drug times did not differ significantly according to mode of transportation or race. Door-
to-drug times did differ significantly according to sex; median times were 30 minutes for males 
and 42 minutes for females. Additionally, door-to-drug times differed significantly according to 
age; median times were 30 minutes for patients less than 70 years old and 45 minutes for patients 
70 years or older. 
 
Table 4. Time between arrival at the hospital and start of thrombolytic therapy 
 
 
Discussion 
 
With a mean symptom-to-door time of 3.8 hours, some patients in the sample had already lost 
maximal benefit from thrombolytic therapy, exceeding both the GUSTO and the Food and Drug 
Administration recommendations that patients receive thrombolytic therapy within 90 minutes 
and 3 hours, respectively, of the onset of signs and symptoms of AMI. This area is one in which 
patients need to take more initiative. Several studies9,10,14,15,19-21 found that the elderly and 
women are more likely to have longer symptom-to-door times, a situation that may compound 
delays in the start of thrombolytic therapy. Meischke et al22 found that patients who were less 
educated or who felt more embarrassed about going to the emergency department were more 
likely than other patients to delay action for treatment of signs and symptoms. Interestingly, 
patients prompted by health professionals to go to the emergency department because of signs or 
symptoms of AMI were less likely than other patients to report an intention to delay seeking 
treatment if similar signs or symptoms occurred in the future.22 
 
Perhaps awareness programs designed to teach the signs and symptoms of AMI and stress the 
importance of going to the hospital as soon as possible after the onset of signs or symptoms 
suggestive of AMI should be implemented.23-25 Alonzo and Reynolds" suggest strategies for 
community interventions to reduce symptom-to-door time that are based on regulation of 3 
components: knowledge, behavior, and emotion. One of the 7 interventions they describe is the 
need to pay special attention to particular social groups, with a focus on the different needs of 
females and the elderly. The elderly know the least about coronary heart disease and are at the 
greatest risk for poor outcomes. Alonzo and Reynolds also discuss the need to educate the public 
to recognize not only the signs and symptoms of AMI, but also the emotional sequelae that often 
distort clear judgment at the time of onset of such signs and symptoms. 
 
In addition, as per ACC/AHA recommendations, patients should use the 911 ambulance and 
emergency medical services system. As indicated by our study, use of emergency medical 
services for transport to the hospital helps lower door-to-ECG times. Although not demonstrated 
in our study, with the shorter door-to-ECG times, overall door-to-drug times might decrease if 
patients with signs and symptoms of AMI were transported by ambulance. 
 
Overall, Alamance Regional Medical Center is efficient in rapidly obtaining ECGs for patients 
with suspected AMI. For 76.1% of all patients, ECGs were obtained within 10 minutes of arrival 
at the hospital, thus meeting ACC/AHA recommendations. However, patients transported by 
private vehicle had longer door-to-ECG times than did patients transported by ambulance. One 
reason for this time difference may be the fact that the emergency department receives 
information from paramedics to prepare for incoming patients with suspected AMI. This practice 
may be the reason differences in ECG-to-drug times and overall door-to-drug times did not differ 
significantly according to mode of transportation. 
 
Overall door-to-drug times did not differ significantly according to race. The relatively small 
number of African Americans in the study sample may account for the lack of racial differences. 
Our results differ from those of Newby et al.9 Further research is needed to determine whether 
race influences treatment times for AMI patients. 
 
Our results indicate that compared with males, females have delays in treatment, in particular, 
longer ECG-to-drug times. This finding is consistent with the results of previous studies.9-13 
Compared with men, women may have different initial signs and symptoms, have different 
precipitating causes of chest pain, and are more likely to be older when signs and symptoms of 
coronary artery disease occur.19 In addition, men may "appear" more ill when they arrive at the 
emergency department, or a perception may exist that men have more risk factors for AMI or an 
increased prevalence of coronary artery disease.12 Arslanian-Engoren27 reported that when 
making triage decisions, emergency department nurses had different perceptions based on sex 
and age about the significance and likelihood of AMI. The nurses associated older male patients 
with cardiac causes requiring more medical attention. These reasons may be why providers may 
treat women less aggressively.27 More research is needed to investigate why women have delays 
in the start of thrombolytic therapy, even after a diagnostic ECG has been obtained. 
 
Older patients had significantly longer door-to-- ECG and ECG-to-drug times than younger 
patients did. Not surprising, the elderly also had longer overall door-to-drug times. These 
findings are consistent with those of previous studies.9,10 In the study by Griffin et al,11 also done 
at Alamance Regional Medical Center, median door-to-ECG times were 8 minutes for patients 
70 years or older and 2.5 minutes for patients less than 70 years old, and median door-to-drug 
times were 49 minutes and 30 minutes, respectively. 
 
Perhaps older patients, without the help of friends or family members, cannot articulate their 
signs and symptoms to the emergency department staff as well as younger patients can. Older 
patients more often have atypical signs and symptoms that may mask the correct diagnosis.28 The 
signs or symptoms may be vague or poorly localized. Patients may have dyspnea, diaphoresis, 
syncope, confusion, altered mental status, weakness, fatigue, or restlessness.28 The additional 
time required to obtain a history, move the patient to the treatment area, and prepare the patient 
for ECG might account for longer door-to-ECG times for older patients. Because older patients 
have more relative contraindications to treatment with thrombolytics and more comorbid 
conditions than younger patients do, additional delay may occur in determining the suitability of 
thrombolytic therapy. However, outcomes in older patients can be markedly improved by 
decreasing time to treatment.9 
 
Study Limitations 
 
Nonsignificant results in subgroup analyses may not indicate lack of differences, but instead may 
indicate lack of power. Point estimates are less stable with smaller sample sizes. A larger sample 
size would provide more confidence in the reliability of our results. Without a sufficiently 
powered, controlled, randomized study, factors such as mode of transportation to the emergency 
department, age, sex, and race cannot be cited as factors influencing treatment times. Although 
the differences in door-to-ECG and ECG-to-drug times may be associated with the variables 
examined, other variables associated with particular subgroups may have influenced these times. 
 
The low door-to-ECG times in our study may not be attainable in all hospitals. Alamance 
Regional Medical Center uses a single thrombolytic agent as the standard care for reperfusion in 
patients with AMI. Differences in door-to-drug times may vary for hospitals that use more than 
one thrombolytic agent or have primary percutaneous transluminal coronary angioplasty 
available as a choice for reperfusion. 
 
We did not determine the accuracy of the medical center in the diagnosis of AMI. A future study 
would be required to determine whether sacrifices in accuracy occurred as a result of efforts to 
treat patients rapidly. Examining the ECGs of patients who did not have a diagnosis of AMI 
made in the emergency department would reveal whether such inaccuracies in diagnosis 
occurred. 
 
Conclusion 
 
Our results provide insights into factors associated with delays in treatment of patients with 
suspected AMI at one community hospital. Interventions must be aimed at ensuring that all 
patients, especially those at high risk for long delays, such as the elderly and women, receive 
timely evaluation and treatment. Healthcare providers should be more aware of the association 
between delays in treatment and the age and sex of a patient. In addition, community 
intervention may help facilitate shorter symptom-to-door times for all patients and thus 
maximize the benefits of thrombolytic therapy. 
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